Wall Street Zen Upgrades Personalis (NASDAQ:PSNL) to Hold

Personalis (NASDAQ:PSNL) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

Other equities analysts have also issued reports about the company. Morgan Stanley boosted their target price on Personalis from $9.00 to $11.00 and gave the stock an “equal weight” rating in a research report on Monday, December 1st. Lake Street Capital reiterated a “buy” rating and issued a $11.00 price target on shares of Personalis in a research report on Wednesday, November 5th. HC Wainwright boosted their price objective on shares of Personalis from $8.50 to $10.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Needham & Company LLC upped their target price on shares of Personalis from $7.00 to $10.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Finally, Guggenheim increased their target price on shares of Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Monday. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.71.

Personalis Stock Performance

PSNL opened at $9.37 on Friday. The company has a fifty day moving average price of $9.23 and a two-hundred day moving average price of $7.58. The firm has a market capitalization of $832.06 million, a PE ratio of -10.65 and a beta of 1.96. Personalis has a 52 week low of $2.83 and a 52 week high of $11.50.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.04. Personalis had a negative return on equity of 38.25% and a negative net margin of 106.92%.The business had revenue of $14.50 million for the quarter, compared to analyst estimates of $13.31 million. Equities analysts forecast that Personalis will post -1.4 EPS for the current year.

Insider Activity at Personalis

In related news, CFO Aaron Tachibana sold 103,668 shares of the firm’s stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $10.78, for a total transaction of $1,117,541.04. Following the sale, the chief financial officer directly owned 164,458 shares in the company, valued at $1,772,857.24. This trade represents a 38.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Christopher M. Hall sold 29,612 shares of the business’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $8.99, for a total transaction of $266,211.88. Following the completion of the sale, the chief executive officer directly owned 148,486 shares in the company, valued at $1,334,889.14. This represents a 16.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 134,481 shares of company stock worth $1,397,564 over the last 90 days. Corporate insiders own 3.80% of the company’s stock.

Hedge Funds Weigh In On Personalis

A number of large investors have recently added to or reduced their stakes in the company. Legal & General Group Plc bought a new stake in shares of Personalis in the second quarter valued at about $30,000. Ameritas Investment Partners Inc. bought a new position in shares of Personalis during the second quarter worth about $34,000. BNP Paribas Financial Markets raised its position in Personalis by 406.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after buying an additional 5,177 shares during the last quarter. Focus Partners Wealth bought a new stake in Personalis in the 1st quarter valued at approximately $47,000. Finally, Farther Finance Advisors LLC bought a new stake in Personalis in the 3rd quarter valued at approximately $66,000. Institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.